The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Opsalin: A phase II placebo (Pbo)-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with carboplatin (Cb) and paclitaxel (P).
Michael J. Birrer
No relevant relationships to disclose
Igor Bondarenko
No relevant relationships to disclose
Sergei Tjulandin
No relevant relationships to disclose
Ignace Vergote
No relevant relationships to disclose
David Cibula
No relevant relationships to disclose
Isabelle Ray-Coquard
Consultant or Advisory Role - PharmaMar; Roche
Research Funding - PharmaMar; Roche
Nicoletta Colombo
No relevant relationships to disclose
Aurore Allard
Employment or Leadership Position - Sanofi
Corina Oprea
Employment or Leadership Position - Sanofi
Augustin A. Rey
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Cristiana Sessa
Consultant or Advisory Role - Sanofi (U)
Research Funding - Sanofi
Eric Pujade-Lauraine
No relevant relationships to disclose